Business Context and Reporting Period
This Form 8-K was filed by AmerisourceBergen Corporation (now Cencora, Inc.) on April 20, 2023. The report discloses a strategic transaction involving the acquisition of OneOncology, a network of oncology practices, in partnership with TPG, a global alternative asset management firm.
Key Financial Metrics
The filing details a specific capital commitment rather than periodic financial performance metrics such as revenue or profit.
- Investment Commitment: Approximately $685 million in cash.
- Equity Stake: Approximately 35% minority interest in the joint venture.
- Transaction Type: Cash acquisition subject to customary adjustments.
Material Changes
The primary material change is the agreement to acquire OneOncology from General Atlantic and its other owners. This represents a new strategic entry into the oncology practice network space through a joint venture structure.
Outlook, Risks, and Contingencies
- Closing Timeline: The transaction is expected to close by the end of September 2023.
- Conditions Precedent: Closing is subject to customary conditions, including the receipt of required regulatory approvals.
- Regulatory Disclosure: The information provided is furnished under Regulation FD and is not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting its incorporation by reference in other filings.
Investor Verification Checklist
- Verify the final closing date, as the current target is end of September 2023.
- Confirm receipt of all necessary regulatory approvals required for the transaction.
- Review the final purchase price, noting it is subject to customary adjustments from the $685 million estimate.
- Monitor the operational integration of OneOncology into the joint venture structure.